Rate Video

ASCO 2020 | Targeted therapy in NSCLC at ASCO 2020

Riyaz Shah • 19 Jun 2020

Lung Cancer Non-Small Cell Lung Cancer Osimertinib

Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, gives his thoughts on the data coming from the ADAURA study (NCT02511106) and other targeted therapies in the treatment of non-small cell lung cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

NICE rejection of osimertinib: what does this mean for EGFR+ NSCLC in the UK?

Riyaz Shah • 29 Jan 2020

Radiotherapy: do WBRT/PCI still have a role in NSCLC/SCLC?

Riyaz Shah • 29 Jan 2020

Resourcing and differing opinions for treating NSCLC with brain mets

Riyaz Shah • 29 Jan 2020

Management of frontline ALK+ NSCLC: brigatinib vs. alectinib

Riyaz Shah • 29 Jan 2020

Related Videos

IASC WCLC 2021: CX-2029 and AMG 757 for lung cancer

Melissa Johnson • 8 Jan 2021

Key lung cancer updates: KRAS(G12C) inhibitors and ADCs

Melissa Johnson • 8 Jan 2021

NGS key for optimal lung cancer treatment

Melissa Johnson • 8 Jan 2021

Updates from the Sarah Cannon Research Institute

Melissa Johnson • 8 Jan 2021